Results 31 to 40 of about 85,259 (288)

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45

open access: yesNature Communications, 2018
Malaria protein Pfs48/45 is a promising transmission-blocking antigen targeted by antibodies. Here, the authors determine the structure of its transmission-blocking epitope I, and generate a humanized monoclonal antibody that binds Pfs48/45 with high ...
Prasun Kundu   +10 more
doaj   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

open access: yes, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S.   +6 more
core   +2 more sources

A monoclonal antibody reacting with human basophils [PDF]

open access: yesBlood, 1987
Abstract Bsp-1 is an IgM murine monoclonal antibody raised against the human erythroblastic leukemia cell line (HEL) that reacts with basophils but not neutrophils or eosinophils. Western blotting techniques showed that Bsp-1 reacts with a 45-kilodalton surface antigen on HEL cells.
Jan Nelson   +3 more
openaire   +4 more sources

Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma

open access: yesCellular Physiology and Biochemistry, 2013
Background: Rituximab, a mouse Fab and human Fc chimeric antibody, has been widely used to treat Non-Hodgkin's lymphoma (NHL). However, only 48% of patients respond to the treatment and complete response rate is below 10%.
Haifeng Zhang   +5 more
doaj   +1 more source

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

open access: yesBioTechniques, 2020
Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future ...
Liaqat Ali   +9 more
doaj   +1 more source

Humanized monoclonal antibodies

open access: yes, 2023
Humanized monoclonal antibodies.
openaire   +1 more source

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

open access: yes, 2019
Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y.   +2 more
core   +1 more source

A monoclonal antibody reactive with human eosinophils [PDF]

open access: yesBlood, 1986
Abstract EO-1, an IgGl murine monoclonal antibody raised against human eosinophilic leukemia cells, reacts with eosinophils, basophils, platelets, and a few (2%) mononuclear cells but not with neutrophils. In the bone marrow, mature and immature eosinophils and basophils express the EO-1 antigen, whereas immature myeloid cells do not ...
Jacqueline Breard   +9 more
openaire   +4 more sources

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva (TM)): Mechanisms of action [PDF]

open access: yes, 2004
Psoriasis is a chronic, incurable, auto-immune disorder with cutaneous manifestations. New evidence on the central role of the immune system in the pathogenesis of psoriasis increasingly provides insight into pathogenic steps that can be modulated to ...
Caro, I.   +7 more
core   +1 more source

Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

open access: yesCase Reports in Immunology, 2019
Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus.
Cesar Daniel Alonso-Bello   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy